Turning Point Therapeutics Names Heather Adams as Vice President of Human Resources
SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Heather Adams as vice president of Human Resources, effective today. Ms. Adams has more than 20 years of human resources experience, primarily in the health care industry across multiple biotechnology and medical device companies.
“As we grow the company, Heather will play a key role in our efforts to develop our team and build the capabilities necessary for our future,” said Dr. Athena Countouriotis, president and chief executive officer. “One of the key investments we can make at this stage –with a pipeline of four advancing drug candidates -- is to focus on our team and future employment needs. I look forward to having Heather as our partner on this journey.”
Ms. Adams will be responsible for all aspects of human resource management, including organizational development, talent management, staffing and compensation. She joins the company from Bionano Genomics, a publicly traded genomics analysis company where she served as chief administrative officer, responsible for administrative functions including human resources. She previously served in senior human resources positions for life sciences companies of various sizes, including Illumina, Micrus Endovascular and AngioScore. Early in her career, she was a researcher in the areas of protein chemistry, animal physiology and liver cell discovery, resulting in several publications in scientific journals.
“I look forward to working with Athena and the entire management team to help shape the future of Turning Point Therapeutics,” said Ms. Adams. “We operate in a competitive biotech environment and our goal will be to maintain an advantage through initiatives that help develop our existing employees’ capabilities as well as attract additional talented team members to join the company.”
About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor in IND-enabling studies. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and therapeutic potential of Turning Point Therapeutics’ drug candidates, the progress of Turning Point Therapeutics’ development programs, and plans regarding future activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.